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Introduction: Systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) are chronic immune-mediated
disorders complicated by vascular organ damage. The aim of this study was to examine the serum levels of the
markers of neoangiogenesis: endostatin and vascular endothelial growth factor (VEGF), in our unselected cohorts of
SSc and MCTD.
Methods: Sera of SSc patients (N = 298) and MCTD patients (N = 162) from two longitudinal Norwegian cohorts
were included. Blood donors were included as controls (N = 100). Circulating VEGF and endostatin were analyzed
by enzyme immunoassay.
Results: Mean endostatin levels were increased in SSc patients 93.7 (37) ng/ml (P < .001) and MCTD patients 83.2
(25) ng/ml (P < .001) compared to controls 65.1 (12) ng/ml. Median VEGF levels were elevated in SSc patients 209.0
(202) pg/ml compared to MCTD patients 181.3 (175) pg/ml (P = .017) and controls 150.0 (145) pg/ml (P < .001).
Multivariable analysis of SSc subsets showed that pulmonary arterial hypertension (coefficient 15.7, 95 % CI: 2.2–29.2,
P = .023) and scleroderma renal crisis (coefficient 77.6, 95 % CI: 59.3–100.0, P < .001) were associated with elevated
endostatin levels. Multivariable analyses of MCTD subsets showed that digital ulcers were associated with elevated
endostatin levels (coefficient 10.5, 95 % CI: 3.2–17.8, P = .005). The risk of death increased by 1.6 per SD endostatin
increase (95 % CI: 1.2–2.1, P = .001) in the SSc cohort and by 1.6 per SD endostatin increase (95 % CI: 1.0–2.4, P = .041) in
the MCTD cohort after adjustments to known risk factors.
Conclusions: Endostatin levels were elevated in patients with SSc and MCTD, particularly SSc patients with pulmonary
arterial hypertension and scleroderma renal crisis, and MCTD patients with digital ulcers. Elevated endostatin levels
were also associated with increased all-cause mortality during follow-up in both groups of patients. We propose that
endostatin might indicate the degree of vascular injury in SSc and MCTD patients.* Correspondence: silje.reiseter@medisin.uio.no
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Systemic sclerosis (SSc) is a chronic multiorgan disease
characterized by vasculopathy, progressive fibrosis of the
skin and internal organs and distinct serum autoanti-
bodies [1, 2]. The primary event in SSc is assumed to be
vascular injury [3], which leads to clinical manifestations
such as Raynaud’s phenomenon and digital ulcers [4].
Mortality is increased and mainly driven by pulmonary
arterial hypertension (PAH) and pulmonary fibrosis [5].
Microangiopathy is thought to be responsible for the life-
threatening organ involvement, such as PAH, scleroderma
renal crisis (SRC), cardiomyopathy, gastric antrial vascular
actasia [3] and possibly also pulmonary fibrosis [6].
Vascular injury has an impact in other connective tis-
sue diseases (CTDs) and is particularly evident in mixed
connective tissue disease (MCTD), a chronic immune-
mediated disease associated with anti-U1-RNP autoanti-
bodies and clinical features from SSc, systemic lupus
erythematosus (SLE) and polymyositis (PM). MCTD ap-
pears to be genetically distinct from other CTDs [7], but
there is an ongoing debate whether it should be catego-
rized as a distinct disease, an overlap syndrome or an
undifferentiated CTD [8]. Even though organ involve-
ment in MCTD is more extensive than initially de-
scribed, organ involvement is less severe than in SSc [9].
The vasculopathy in MCTD has been found to resemble
the vasculopathy found in SSc [10] and it has been sug-
gested that there is an association between pulmonary
hypertension (PH) and anti-U1-RNP autoantibodies in
SSc [11] and SLE [12]. Identifying SSc and MCTD pa-
tients at risk of developing serious vascular organ dam-
age could improve patient outcome. Hence, there is a
growing interest in markers that may predict vasculopa-
thy [13].
In healthy tissue vascular injury causes hypoxia, which
induces proteins in the vascular endothelial growth
factor (VEGF) family. VEGF-A (usually referred to as
VEGF) is released by a variety of cells including fibro-
blasts, macrophages, neutrophils, endothelial cells and T
cells, and is involved in numerous steps of neoangio-
genesis (13). Endostatin is the most potent inhibitor of
VEGF-induced angiogenesis. It is a peptide derived from
collagen XVIII, produced by fibroblasts and primarily
found in the basement membranes of the skin and lungs
[14], both of which are tissues involved in SSc and
MCTD. Previous studies have shown increased serum
levels of VEGF and endostatin in SSc [15] and MCTD
[16], indicating an altered regulation of angiogenesis in
these diseases. However, the previous studies of VEGF and
endostatin in SSc and MCTD were performed in small-
scale cohorts, and the correlation to clinical parameters
has been somewhat discrepant [17–19] and some have
been contradictive [17, 20]. An additional table shows pre-
vious data in more detail (see Additional file 1) [16–24].The aim of this study was to assess the serum levels of
endostatin and VEGF in two large, well-characterized
and largely unselected longitudinal CTD cohorts; the
Oslo University Hospital (OUH) SSc cohort [25, 26] and
the Norwegian nationwide MCTD cohort [27–29]. Se-
rum levels of endostatin and VEGF of SSc and MCTD
patients were compared with controls. Our basic hy-
pothesis was that VEGF and endostatin were associated
with vasculopathy-related features like digital ulcers,
PAH, SRC and possibly also pulmonary fibrosis, in both
diseases. Hence, we wanted to explore the associations
of these clinical parameters and all-cause mortality with
endostatin and VEGF levels.
Methods
Study cohorts
Sera of SSc patients (N = 298) from the previously de-
scribed Oslo University Hospital (OUH) SSc cohort were
assessed [25, 30, 31]. The OUH SSc cohort is an obser-
vational prospective study cohort which includes all con-
senting SSc patients seen at OUH since 2008. Patients
included in the cohort have annual follow-up visits at
OUH where clinical parameters, pulmonary function
tests (PFTs), lung high-resolution computed tomography
(HRCT), echocardiography, and right-sided heart cath-
eterization (RHC) data are systematically recorded and
stored in the Norwegian Systemic Connective Tissue
Disease and Vasculitides Registry (NOSVAR) [26]. Se-
rum samples are taken at inclusion and stored in the
NOSVAR biobank. All SSc patients included in this study
fulfilled the 2013 European League Against Rheumatism/
American College of Rheumatology (EULAR/ACR) classi-
fication criteria for SSc [25, 32].
Sera of MCTD patients (N = 162) from the previously
described unselected Norwegian nationwide MCTD co-
hort [7, 27–29] (n = 135) and NOSVAR (n = 27) were
similarly assessed. The Norwegian nationwide MCTD
cohort recruited patients from Departments of Rheuma-
tology from 2005 to 2008, while NOSVAR recruited pa-
tients from OUH from 2008 to 2012. Inclusion criteria
were age 18 and fulfillment of at least one of the three
criteria sets of MCTD, the modified Sharp’s criteria [33],
the criteria of Alarcón-Segovia or Kasukawa [9], and the
exclusion of another CTD [29]. Consenting blood do-
nors from the OUH blood bank were included as con-
trols (N = 100).
Clinical parameters
SSc patients were categorized as diffuse cutaneous SSc
(dcSSc) or limited cutaneous SSc (lcSSc) [34]. Disease
onset was defined as the onset of the first non-Raynaud’s
symptom. Clinical parameters recorded included per-
centage of predicted full vital capacity (FVC) and per-
centage of predicted diffusing capacity of the lung for
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HRCT: see below), digital ulcers, SRC and PH segregated
into two well-defined groups; PAH and PH due to lung
disease. In the MCTD cohort, clinical parameters in-
cluded percentage of predicted FVC and DLCO, pul-
monary fibrosis, digital ulcers, PAH and PH due to lung
disease. Digital ulcers were scored positive if ulcers were
present at least once during the disease course. Precapil-
lary PH was defined according to the updated European
Society of Cardiology (ESC) criteria by mean pulmonary
artery pressure (mPAP) ≥25 mm HG and pulmonary
wedge pressure ≤15 mm HG by RHC at rest [35].
Patients in our SSc cohort have an annual clinical
follow-up at OUS, they are referred to RHC when it is
clinically indicated based on physical examination, PFT
results, 6-minute walk tests and echocardiogram results.
Echocardiogram results were available in 294 patients
(99 %). RHC was performed in 96 patients (32 %). In the
analyses we included patients classified as having pul-
monary arterial hypertension (PAH). PAH is character-
ized by the presence of precapillary PH in the absence of
other causes of precapillary PH such as PH due to lung
diseases, chronic thromboembolic PH, or other rare dis-
eases [35]. Vital status at the end of the study was ob-
tained from the National Population Register of Norway.
High-resolution computed tomography (HRCT) analysis of
the lungs and pulmonary function tests (PFTs)
The presence of fibrosis was evaluated according to the
CT criteria of interstitial lung disease recommended by
The Nomenclature Committee of the Fleischner Society
[36]. HRCT was obtained by inclusion in both cohorts,
and reviewed on a Picture Archiving and Communication
System (PACS) screen independently and in random
order by two experienced readers. HRCT were available
in 252 of 298 patients (85 %) in the SSc cohort and in
148 of 162 patients (91 %) in the MCTD cohort. Pul-
monary function tests were performed according to
established guidelines [37, 38].
Blood samples
Blood samples were centrifuged at room temperature after
30 minutes and serum aliquots were stored at −70 °C until
assayed. Circulating VEGF and endostatin were analyzed
by enzyme immunoassay (R&D Systems, Stillwater, MN,
USA). The detection limit for endostatin was 80 pg/ml
and intra- and interassay coefficients <10 %.
Statistical analyses
Serum levels of endostatin were compared by means
(M) and standard deviation (SD) in all groups. Statistical
differences between MCTD, SSc and controls were ana-
lyzed by one-way ANOVA. Post hoc comparisons were
performed using Tukey’s test. Serum levels of VEGF didnot have a normal distribution and were presented as
median (Mdn) and interquartile range (IQR). Com-
parisons between the three groups were analyzed by
Kruskal-Wallis test. Estimations of the effects of various
clinical manifestations on serum endostatin levels were
performed by linear regression analyses. We included
clinical parameters with evident vasculopathy; digital
ulcers, PAH and SRC. Since it has been proposed that
vasculopathy is involved in pulmonary fibrosis this par-
ameter was included together with the accompanying
lung parameters; percentage of predicted FVC and per-
centage of predicted DLCO. Known risk factors for SRC
and PAH was also included in the model. In the linear
regression analyses we included patients with established
PAH (N = 24) and SRC (N = 11) at the year of serum
sampling. Univariable and multivariable logistic regression
analyses were performed to explore the predictive value of
endostatin. Patients who developed PAH and SRC the
same year as serum sampling or later were included in the
logistic regression analyses (N = 16 and N = 6, res-
pectively). An additional graph shows when patients were
diagnosed with PAH and SRC in relation to serum sam-
pling (Additional file 2). Variables that were significant in
univariable analyses were included in multivariable ana-
lysis. Using a manual backward elimination procedure,
variables at a significant level of P < .25 in the univari-
able analyses were considered a candidate for the multi-
variable model in conjunction with age and gender.
The association was quantified by the odds ratio (OR)
with its 95 % confidence interval (CI). With regard to
follow-up time, participants were followed from the
date of inclusion in the cohort until death or end of
follow-up on 31 October 2014. Kaplan-Meier survival
curves were used to determine difference in survival
between tertiles of endostatin levels and were estimated
by the log-rank test. A multivariable Cox regression
model was performed to control for multiple con-
founders. The proportional hazard assumptions were
tested by plotting the logarithm of the integrated haz-
ards (log–log survival plots). The effects were quanti-
fied by hazard ratio (HR) with its 95 % CI. Known risk
factors were included in the multivariable logistic [39,
40] and Cox regression analyses [30, 41]. The sig-
nificance level was set at P ≤ .05. Data extraction and ana-
lyses were conducted using SPSS version 22 (IBM SPSS,
Armonk, NY, USA) and STATA version 22 (StataCorp,
College Station, TX, USA).
Ethics
The study was approved by the Norwegian Regional
Committee for Medical and Health Research Ethics and
conducted in accordance with the guidelines of the
Helsinki II declaration. All patients have given informed
written consent to participate in the study.
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Serum endostatin and VEGF levels in the study cohorts
Circulating endostatin and VEGF levels were assessed in
the OUH SSc cohort (N = 298) and in the Norwegian
MCTD cohort (N = 162) (Table 1). Mean (SD) serum
endostatin was higher in SSc 93.7 (37) ng/ml than MCTD
83.2 (25) ng/ml (P = .001) and controls 65.1 (12) ng/ml
(P < .001). Mean serum endostatin was also higher in
MCTD compared to controls (P < .001) (Fig. 1a). The SSc
patients had higher median VEGF 209.0 (IQR 202) pg/ml
than both MCTD 181.3 (175) pg/ml (P = .017) and con-
trols 150.4 (145) pg/ml (P < .001). VEGF levels did not dif-
fer between MCTD and controls (Fig. 1b).
Association between clinical parameters and serum
endostatin and VEGF in the SSc cohort
In univariable analyses dcSSc (Fig. 2a), SRC (Fig. 2b) and
PAH (Fig. 2c) were associated with elevated endostatin
levels, while percentage of predicted DLCO was negativelyTable 1 Demographics and clinical parameters of the MCTD
and SSc cohorts
SSc MCTD
Patients, N 298 162
Females, N (%) 243 (82) 128 (79)
Diffuse cutaneous SSc, N (%) 78 (26) N/A
Age at diagnosis, years, M (SD) 48.3 (15.4) 35.4 (15.7)
Age at blood sampling, M (SD) 56.0 (13.8) 44.7 (14.9)
Disease duration at sampling, years, Mdn
(IQR)
4.0 (9) 7.0 (7)
Deceased, N (%) 58 (20) 14 (9)
Observation time, months, M (SD) 55.0 (28.7) 98.8 (27.4)
Classification criteria:
ACR/EULAR 2013 SSc, N (%) 298 (100) N/A
Alarcon, N (%) N/A 143 (88)
Sharp, N (%) N/A 151 (93)
Kasukawa, N (%) N/A 142 (88)
Pulmonary fibrosis at sampling, N (%) 103/252 (40) 52/148 (35)
% of predicted FVC, N (%) 297 (100) 146 (90)
% of predicted FVC, M (SD) 94,7 (20,5) 92.1 (18.5)
% of predicted DLCO, N (%) 295 (99) 142 (88)
% of predicted DLCO, M (SD) 68.2 (21.7) 73.8 (16.4)
Digital ulcers, N (%) 132/278 (44) 50/155 (32)
Precapillary pulmonary hypertension, N (%) 44 (15) 3 (.05)
Pulmonary arterial hypertension, N (%) 32 (10.7) 2 (.04)
Scleroderma renal crisis, N (%) 12 (4) 0 (0)
MCTD mixed connective tissue disease, SSc systemic sclerosis, N numbers,
N/A not applicable, M mean, SD standard deviation, Mdn median, IQR interquartile
range, FVC forced vital capacity, DLCO diffusing capacity of the lungs for
carbon monoxideassociated with endostatin levels (Table 2). In the multiple
linear regression analysis, PAH and SRC were significantly
associated with elevated endostatin levels (Table 2). The
strongest effect was SRC with a mean difference of
77.6 ng/ml in endostatin levels between patients with and
without SRC.
An inverse association was found between percentage
of predicted DLCO and elevated levels of VEGF pg/ml
(coefficient - .14, 95 % CI −2.5, −.3, P = .013). No other
associations were found between serum VEGF and clin-
ical parameters in the SSc cohort.
Association between clinical parameters and serum
endostatin and VEGF in the MCTD cohort
Pulmonary fibrosis (Fig. 3a) and digital ulcers (Fig 3b)
were associated with high endostatin serum levels, while
a negative association was found with percentage of
predicted FVC and DLCO in the univariable analyses
(Table 3). In the multivariable linear regression analyses
digital ulcers remained significant, indicating a mean
difference of 10.5 ng/ml in endostatin levels in patients
with and without digital ulcers. No significant associations
were found between clinical parameters and serum VEGF
in the MCTD cohort.
Predictive value of endostatin in SSc
Logistic regression was performed to explore the pre-
dictive value of endostatin. When assessing all SSc pa-
tients who developed PAH after or within the year of
endostatin samples were taken, no significant association
was found. However, when including patients that devel-
oped PAH within the first 2 years after blood sampling
we found for each one SD increase in endostatin levels the
odds of developing PAH increased with 70 % (OR = 1.7,
95 % CI: 1.2–2.4, P = .005) (see Additional file 3). The pre-
dictive value of endostatin for PAH development was not
significant in the multivariable analysis. We then assessed
patients who developed SRC after blood sample. All six
cases were diagnosed within 2 years of blood sampling. A
one SD increase in endostatin level in SSc was associated
with a 3.2-fold higher odds (95 % CI: 1.8–5.7, P < .001) of
developing SRC. Endostatin was identified as the only pre-
dictor of SRC after assessing candidates for multivariable
analyses [40] including age, gender, disease duration and
dcSSc (see Additional file 3). Analyzing the predictive value
of endostatin in the MCTD cohort was not applicable.
All-cause mortality and endostatin levels in the
SSc cohort
During 5 years of follow-up 48 patients died and during
10 years of follow-up 58 SSc patients died. SSc patients
were divided in tertiles of endostatin levels. The 5-year
cumulative survival rate was 94 % (95 % CI: 87–98 %) in
the first tertile, 87 % (95 % CI: 77–92 %) in the second
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Fig. 1 a-b Endostatin and vascular endothelial growth factor (VEGF) serum levels in systemic sclerosis (SSc), mixed connective tissue disease
(MCTD) and controls
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lative survival rate was 94 % (95 % CI: 90–99 %) in the
first tertile, 64 % (95 % CI: 39–86 %) in the second tertile
and 28 % (95 % CI: 0–56 %) in the third tertile (log rank
P < .001) (Fig. 4). The risk of death increased by 1.6 per
SD endostatin in multivariable Cox regression analysis
when adjusting for the confounding effects of age, gen-
der, disease duration, dcSSc, pulmonary fibrosis, PH and
SRC (95 % CI: 1.2–2.1 %, P = .001).All-cause mortality and endostatin levels in the MCTD
cohort
Similar analyses were performed in the MCTD group.
During 10 years of follow-up 14 MCTD patients died
and the 10-year cumulative survival rate was 92 % (95 %
CI: 85–99 % in the first tertile, 91 % (95 % CI: 77–
100 %) in the second tertile and 77 % (95 % CI: 62–92 %
in the third tertile. Following multivariable Cox regres-
sion a one SD increase in endostatin level increased the
risk of death by 1.6 (95 % CI: 1.0–2.4 %, P = .041) when
adjusting for the confounding effects of age, gender, dis-
ease duration, pulmonary fibrosis and PH.0
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Fig. 2 a, b and c Mean endostatin levels in different systemic sclerosis (SScDiscussion
Identifying SSc and MCTD patients at risk of developing
serious vascular organ damage could improve patient
outcome. The main findings of this study were that
increased circulating endostatin, but not VEGF was in-
dependently associated with PAH and SRC in SSc pa-
tients and with digital ulcers in MCTD patients. Survival
analysis showed higher all-cause mortality in both SSc
and MCTD patients with increased endostatin levels.
Endostatin has been found to be increased in MCTD
and SSc compared to controls in previous small-scale
studies [16, 18, 19, 23, 24]. The present study extends
these previous findings in a much larger sample size and
shows a strong association with severe vascular organ
damage and mortality during long-term follow-up.
We found higher levels of endostatin in SSc than in
MCTD, possibly reflecting that the inhibition of angio-
genesis is greater in SSc than in MCTD [14]. In line with
other studies [17–19, 23], we found serum VEGF levels
to be elevated in SSc compared to controls. Elevated
VEGF levels in blood and skin of SSc patients have pre-
viously been suggested to contribute to the chaotic capil-
lary morphology seen in these patients [42]. In contrasta renal crisis
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Table 2 Association between clinical parameters and circulating endostatin in the SSc cohort
Clinical manifestations Univariable Multivariablea
Regression coefficient 95 % CI P value Regression coefficient 95 % CI P value
% of predicted FVC −.14 −.34, −.07 .192
% of predicted DLCO −.33 −.52, −.15 .001 −.18 −.35, −.002 .048
dcSSc vs. lcSSc 10.0 .6, 19.5 .037
Pulmonary arterial hypertension 29.3 14.4, 44.2 < .001 15.7 2.2, 29.2 .023
Scleroderma renal crisis 74.6 54.1, 95.0 < .001 77.6 59.3, 100.0 < .001
SSc systemic sclerosis, CI confidence interval, FVC forced vital capacity, DLCO diffusing capacity of the lungs for carbon monoxide, dsSSc diffuse cutaneous SSc,
lcSSc limited cutaneous SSc
aVariables in the final multivariable regression model: percentage of predicted DLCO, pulmonary arterial hypertension, scleroderma renal crisis, age and gender
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between VEGF levels and clinical parameters in the SSc
or MCTD cohorts. Importantly, our findings support the
study by Hummers et al. showing increased levels of
endostatin and not VEGF in SSc patients with PH [23].
The mechanisms behind PAH and SRC development
in SSc are not fully understood. The pathology in SSc
PAH is described as an obliterative vasculopathy with in-
timal proliferation, medial hyperplasia, and adventitial fi-
brosis in the small pulmonary arterioles [43], while
thrombotic microangiopathic vasculopathy has been ob-
served in SRC [44]. The current endostatin data sup-
ports the hypothesis that dysregulated angiogenesis may
play a role in both PAH and SRC. Moreover, recent
studies have suggested that endostatin may influence the
regulation of matrix metalloproteinases [45], which
could contribute to vascular remodeling in the SSc tar-
get organs [46].
Previous data from a small MCTD cohort with cases
selected from referral centers showed that the patient
subsets with acrosclerosis and PH had high circulating
VEGF, but endostatin were the same levels as controls
[16]. In the present larger and population-based MCTD
cohort we found an association between digital ulcers
and elevated endostatin levels, implying that the level of
endostatin might reflect the severity of vasculopathy in
MCTD. In the unselected Norwegian MCTD cohort,
PAH was less frequent (two cases in total) than otherTable 3 Association between clinical parameters and circulating end
Clinical manifestations Univariable
Regression coefficient 95 % CI
Pulmonary fibrosis 10.5 1.9, 19.1
% of predicted FVC − .33 −.55, −.12
% of predicted DLCO −.40 −.64, −.16
Digital ulcers 10.7 3.2, 18.2
MCTD mixed connective tissue disease, FVC forced vital capacity, DLCO diffusing ca
aVariables in the final multivariable regression model: digital ulcers, age and genderstudies have shown [47, 48]. Due to the low number we
could not perform analyses involving endostatin and
PAH in the MCTD cohort.
For clinical purposes, we found it of interest to explore
the potential predictive value of endostatin. These ana-
lyses showed that increasing endostatin levels predicted
PAH development within 2 years in SSc patients in the
univariable analysis, but not in multivariable analysis
where age and percentage of predicted DLCO had stron-
ger predictive value. Since both are well-known risk fac-
tors for PAH in SSc [39] there is still a possible role for
endostatin in predicting PAH, but this needs to be fur-
ther investigated in cohorts with larger numbers of PAH
cases. We found endostatin to be the only predictor of
SRC, however due to low number of SRC events (six in
total), results must be carefully interpreted.
The present study is, to our knowledge, the first to
show an association between endostatin and all-cause
mortality in SSc and MCTD. Previous studies have re-
ported elevated endostatin to be associated with in-
creased risk of death in the elderly [49] and a predictor
of all-cause mortality in patients with chronic heart fail-
ure of ischemic origin and poor renal function [50].
A major strength of this study is the large number of
included patients with MCTD and SSc, and the com-
parison of results between two diseases with partly over-
lapping clinical features from the two cohorts. There
was no loss to follow-up. The cohorts are largelyostatin in the MCTD cohort
Multivariablea
P value Regression coefficient 95 % CI P value
.017
.002
.001
.006 10.5 3.2, 17.8 .005
pacity of the lungs for carbon monoxide
a b
Fig. 3 a and b Mean endostatin levels and clinical parameters in mixed connective tissue disease (MCTD)
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that consists of comprehensive clinical data. This gave
us the opportunity to assess a number of relevant pa-
rameters in the multivariable analyses. In addition to the
clinical parameters shown in Tables 2 and 3, we also
assessed age, gender, disease duration, digital ulcers and
pulmonary fibrosis in both cohorts, and sclerodactyly
and puffy hands in the MCTD cohort only.
A limitation of this study was not distinguishing the
proangiogenic and antiangiogenic isoforms of VEGF [51].
Unfortunately, we were not able to assess the associations
of VEGF and endostatin to the clinical vasculopathy fea-
tures cardiomyopathy and gastric antrial vascular actasia
due to missing data in our SSc cohort. We were not able
to compare endostatin to known cardiovascular risk fac-
tors in our study and we were not able, due to missing
data, to adjust for pro-brain natriuretic peptide serum
levels, estimation of glomerular filtration rate levels or
anti-RNA polymerase antibodies. For the parameters SRCFig. 4 Kaplan-Meier curve for tertiles of endostatinin SSc and deaths in MCTD the numbers were low,
weakening the impact of these findings. Finally, the endo-
statin and VEGF measurements were performed cross-
sectionally at different disease durations.
Conclusions
In this study, performed in largely unselected patient co-
horts, we demonstrated that endostatin levels are ele-
vated in SSc and MCTD patients, and associated with
SRC and PAH in SSc patients and digital ulcers in
MCTD patients. High endostatin levels were also associ-
ated with increased all-cause mortality during follow-up
in both groups of patients. Taken together our data fur-
ther underscore the role of dysregulated angiogenesis in
SSc and MCTD and suggest that endostatin could reflect
the degree of vasculopathy in these disorders. Further
studies are warranted to evaluate the potential role of
circulating endostatin as a marker for serious vascular
organ damage in SSc and MCTD patients.
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Additional file 1: Previous studies of endostatin and/or vascular
endothelial growth factor in SSc and MCTD. Listing of previous
studies of endostatin and/or vascular endothelial growth factor levels in
SSc and/or MCTD including methods and main results. (PDF 241 kb)
Additional file 2: Diagnoses of pulmonary arterial hypertension
and scleroderma renal crisis in relation to serum sampling time.
A graph showing time of diagnosis of pulmonary arterial hypertension
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